Replimune Group (NASDAQ:REPL) Trading Up 4.8% – Here’s Why

24 Dec 2025, 17:00 by Sarita Garza · The Markets Daily

Replimune Group, Inc. (NASDAQ:REPL – Get Free Report)’s stock price was up 4.8% on Wednesday . The company traded as high as $10.27 and last traded at $10.1850. Approximately 117,126 shares traded hands during trading, a decline of 97% from the average daily volume of 4,112,682 shares. The stock had previously closed at $9.72.

Analyst Ratings Changes

A number of equities analysts have commented on the company. Piper Sandler upgraded Replimune Group from a “neutral” rating to an “overweight” rating and set a $13.00 target price for the company in a research note on Monday, October 20th. Wedbush raised Replimune Group from a “neutral” rating to an “outperform” rating and raised their price target for the stock from $4.00 to $18.00 in a report on Monday, October 20th. Leerink Partnrs upgraded Replimune Group from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 20th. JPMorgan Chase & Co. upgraded Replimune Group from an “underweight” rating to a “neutral” rating and set a $11.00 target price on the stock in a research note on Monday, October 20th. Finally, HC Wainwright raised shares of Replimune Group from a “neutral” rating to a “buy” rating and set a $12.00 price target for the company in a report on Monday, October 27th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $9.75.

Read Our Latest Analysis on Replimune Group

Replimune Group Trading Up 4.4%

The firm has a 50-day moving average of $9.18 and a 200 day moving average of $7.62. The company has a current ratio of 6.31, a quick ratio of 6.31 and a debt-to-equity ratio of 0.26. The stock has a market capitalization of $796.24 million, a price-to-earnings ratio of -2.93 and a beta of 0.66.

Replimune Group (NASDAQ:REPL – Get Free Report) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.87) by ($0.03). As a group, equities analysts predict that Replimune Group, Inc. will post -2.97 EPS for the current fiscal year.

Insider Activity at Replimune Group

In related news, insider Christopher Sarchi sold 5,208 shares of the business’s stock in a transaction that occurred on Monday, November 17th. The stock was sold at an average price of $9.10, for a total transaction of $47,392.80. Following the sale, the insider owned 123,088 shares of the company’s stock, valued at $1,120,100.80. The trade was a 4.06% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Kapil Dhingra sold 3,169 shares of the stock in a transaction on Tuesday, December 9th. The shares were sold at an average price of $10.40, for a total value of $32,957.60. The SEC filing for this sale provides additional information. Insiders have sold a total of 25,625 shares of company stock valued at $257,607 over the last quarter. Corporate insiders own 5.20% of the company’s stock.

Institutional Trading of Replimune Group

Institutional investors have recently modified their holdings of the company. Tudor Investment Corp ET AL acquired a new position in Replimune Group during the third quarter worth about $87,000. Scientech Research LLC bought a new position in shares of Replimune Group during the 3rd quarter valued at about $102,000. Fcpm Iii Services B.V. grew its stake in shares of Replimune Group by 6.4% in the 3rd quarter. Fcpm Iii Services B.V. now owns 4,158,368 shares of the company’s stock worth $17,424,000 after purchasing an additional 248,672 shares during the last quarter. Braidwell LP grew its stake in shares of Replimune Group by 550.3% in the 3rd quarter. Braidwell LP now owns 2,750,092 shares of the company’s stock worth $11,523,000 after purchasing an additional 2,327,205 shares during the last quarter. Finally, Alliancebernstein L.P. raised its holdings in shares of Replimune Group by 23.4% in the 3rd quarter. Alliancebernstein L.P. now owns 63,540 shares of the company’s stock worth $266,000 after purchasing an additional 12,050 shares in the last quarter. Institutional investors and hedge funds own 92.53% of the company’s stock.

About Replimune Group

(Get Free Report)

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.